{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T06:51:53Z","timestamp":1779259913429,"version":"3.51.4"},"reference-count":164,"publisher":"Elsevier BV","issue":"5-7","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004564","name":"Ministarstvo Prosvete, Nauke i Tehnolo\u0161kog Razvoja","doi-asserted-by":"publisher","award":["451-03-66\/2024-03\/200015"],"award-info":[{"award-number":["451-03-66\/2024-03\/200015"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Histochemica"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.acthis.2024.152183","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T18:30:00Z","timestamp":1721327400000},"page":"152183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Myeloid-derived suppressor cells: Implication in myeloid malignancies and immunotherapy"],"prefix":"10.1016","volume":"126","author":[{"given":"Suncica","family":"Kapor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milica","family":"Radojkovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan F.","family":"Santibanez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.acthis.2024.152183_bib1","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3343\/alm.2021.41.5.479","article-title":"Granulocytic and monocytic myeloid-derived suppressor cells are functionally and prognostically different in patients with chronic myeloid leukemia","volume":"41","author":"Ahn","year":"2021","journal-title":"Ann. Lab Med"},{"issue":"9976","key":"10.1016\/j.acthis.2024.152183_bib2","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.acthis.2024.152183_bib3","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.acthis.2024.152183_bib4","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.acthis.2024.152183_bib5","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1182\/blood-2012-09-458935","article-title":"Selective killing of candidate AML stem cells by antibody targeting of IL1RAP","volume":"121","author":"Askmyr","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.acthis.2024.152183_bib6","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13158","article-title":"Cytarabine-induced TNF\u03b1 promotes the expansion and suppressive functions of myeloid-derived suppressor cells in acute myeloid leukemia.","volume":"95","author":"Bai","year":"2022","journal-title":"Scand. J. Immunol."},{"issue":"3","key":"10.1016\/j.acthis.2024.152183_bib7","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2174\/1574888X11666161226150159","article-title":"Current status of leukemia cytotherapy - exploitation with immune cells","volume":"12","author":"Bao","year":"2017","journal-title":"Curr. Stem Cell Res Ther."},{"issue":"2","key":"10.1016\/j.acthis.2024.152183_bib8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J."},{"issue":"4","key":"10.1016\/j.acthis.2024.152183_bib9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11899-014-0227-0","article-title":"An immune dysregulation in MPN","volume":"9","author":"Barosi","year":"2014","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"12","key":"10.1016\/j.acthis.2024.152183_bib10","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.3390\/cells10123551","article-title":"Progression of Myeloproliferative Neoplasms (MPN): diagnostic and therapeutic perspectives","volume":"10","author":"Baumeister","year":"2021","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.acthis.2024.152183_bib11","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/14728222.2020.1744850","article-title":"The bone marrow stromal niche: a therapeutic target of hematological myeloid malignancies","volume":"24","author":"Behrmann","year":"2020","journal-title":"Expert Opin. Ther. Targets"},{"issue":"4","key":"10.1016\/j.acthis.2024.152183_bib12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3892\/ol.2021.12578","article-title":"New progress in the study of germline susceptibility genes of myeloid neoplasms","volume":"21","author":"Bi","year":"2021","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.acthis.2024.152183_bib13","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000168","article-title":"Myeloid-derived suppressor cells in hematologic diseases: promising biomarkers and treatment targets","volume":"3","author":"Bizymi","year":"2019","journal-title":"Hemasphere"},{"issue":"10","key":"10.1016\/j.acthis.2024.152183_bib14","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/intimm\/dxf081","article-title":"Analysis of the mechanisms of human cytotoxic T lymphocyte response inhibition by NO","volume":"14","author":"Blesson","year":"2002","journal-title":"Int Immunol."},{"key":"10.1016\/j.acthis.2024.152183_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.acthis.2024.152183_bib16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/cancers16010042","article-title":"Chimeric antigen receptor t-cell therapy in acute myeloid leukemia: state of the art and recent advances","volume":"16","author":"Canichella","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.acthis.2024.152183_bib17","article-title":"Practical considerations in clinical application of WHO 5th and ICC classification schemes for acute myeloid leukemia","author":"Chandra","year":"2023","journal-title":"Blood Rev."},{"issue":"3","key":"10.1016\/j.acthis.2024.152183_bib18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00005792-197605000-00005","article-title":"Causes of death in adults with acute leukemia","volume":"55","author":"Chang","year":"1976","journal-title":"Med. (Baltim. )"},{"issue":"11","key":"10.1016\/j.acthis.2024.152183_bib19","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1172\/JCI67580","article-title":"Induction of myelodysplasia by myeloid-derived suppressor cells","volume":"123","author":"Chen","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.acthis.2024.152183_bib20","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.ymthe.2022.02.005","article-title":"Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33\/CD3 T cell engager, ex vivo in MDS and melanoma","volume":"30","author":"Cheng","year":"2022","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.acthis.2024.152183_bib21","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/leu.2013.382","article-title":"Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis","volume":"28","author":"Chi","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.acthis.2024.152183_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055818","article-title":"Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1\/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia","volume":"8","author":"Christiansson","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.acthis.2024.152183_bib23","doi-asserted-by":"crossref","first-page":"5693","DOI":"10.4049\/jimmunol.0900092","article-title":"Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells","volume":"182","author":"Corzo","year":"2009","journal-title":"J. Immunol."},{"issue":"17","key":"10.1016\/j.acthis.2024.152183_bib24","doi-asserted-by":"crossref","first-page":"6884","DOI":"10.1158\/0008-5472.CAN-08-1101","article-title":"BCR\/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair","volume":"68","author":"Cramer","year":"2008","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.acthis.2024.152183_bib25","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.acthis.2024.152183_bib26","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.acthis.2024.152183_bib27","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/cncr.24984","article-title":"Cause of death in patients with lower-risk myelodysplastic syndrome","volume":"116","author":"Dayyani","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.acthis.2024.152183_bib28","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3389\/fimmu.2020.01680","article-title":"The New Era of cancer immunotherapy: targeting myeloid-derived suppressor cells to overcome immune evasion","volume":"11","author":"De Cicco","year":"2020","journal-title":"Front Immunol."},{"issue":"7","key":"10.1016\/j.acthis.2024.152183_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.50","article-title":"Acute myeloid leukemia: a comprehensive review and 2016 update","volume":"6","author":"De Kouchkovsky","year":"2016","journal-title":"Blood Cancer J."},{"issue":"12","key":"10.1016\/j.acthis.2024.152183_bib30","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.acthis.2024.152183_bib31","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/S1470-2045(19)30729-6","article-title":"CAR T-cell product performance in haematological malignancies before and after marketing authorisation","volume":"21","author":"Elsallab","year":"2020","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.acthis.2024.152183_bib32","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/ijc.26123","article-title":"Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer","volume":"130","author":"Eruslanov","year":"2012","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.acthis.2024.152183_bib33","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ebiom.2019.08.025","article-title":"MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers","volume":"47","author":"Fultang","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.acthis.2024.152183_bib34","article-title":"Philadelphia chromosome-negative myeloproliferative chronic neoplasms: is clonal hematopoiesis the main determinant of autoimmune and cardio-vascular manifestations?","volume":"10","author":"Fulvio","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"10","key":"10.1016\/j.acthis.2024.152183_bib35","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s00262-011-1028-0","article-title":"Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13","volume":"60","author":"Gabitass","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.acthis.2024.152183_bib36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-derived suppressor cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol. Res"},{"issue":"3","key":"10.1016\/j.acthis.2024.152183_bib37","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.acthis.2024.152183_bib38","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/jcmm.13326","article-title":"Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib","volume":"22","author":"Giallongo","year":"2018","journal-title":"J. Cell Mol. Med"},{"key":"10.1016\/j.acthis.2024.152183_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101848","article-title":"Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients","volume":"9","author":"Giallongo","year":"2014","journal-title":"PloS ONE"},{"issue":"8","key":"10.1016\/j.acthis.2024.152183_bib40","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s00018-017-2725-4","article-title":"Role of the microenvironment in myeloid malignancies","volume":"75","author":"Goulard","year":"2018","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.acthis.2024.152183_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1117466","article-title":"An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: a first-in-man clinical trial","volume":"14","author":"Grauslund","year":"2023","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.acthis.2024.152183_bib42","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","article-title":"Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression","volume":"120","author":"Groth","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"10","key":"10.1016\/j.acthis.2024.152183_bib43","first-page":"1228","article-title":"Immunotherapy in acute myeloid leukemia: a literature review of emerging strategies","volume":"10","author":"Guarnera","year":"2023","journal-title":"Bioeng. (Basel)"},{"key":"10.1016\/j.acthis.2024.152183_bib44","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/bs.ircmb.2021.09.003","article-title":"The MPL mutation","volume":"365","author":"Guglielmelli","year":"2021","journal-title":"Int Rev. Cell Mol. Biol."},{"issue":"8","key":"10.1016\/j.acthis.2024.152183_bib45","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1177\/1753425920961157","article-title":"Myeloid-derived suppressor cell cytokine secretion as prognostic factor in myelodysplastic syndromes","volume":"26","author":"Han","year":"2020","journal-title":"Innate Immun."},{"issue":"2","key":"10.1016\/j.acthis.2024.152183_bib46","doi-asserted-by":"crossref","first-page":"937","DOI":"10.4049\/jimmunol.0804253","article-title":"Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells","volume":"183","author":"Hanson","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.acthis.2024.152183_bib47","article-title":"Pathogenesis of myeloproliferative neoplasms: role and mechanisms of chronic inflammation","volume":"2015","author":"Hermouet","year":"2015","journal-title":"Mediat. Inflamm."},{"issue":"4","key":"10.1016\/j.acthis.2024.152183_bib48","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.acthis.2024.152183_bib49","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.3390\/cancers12071763","article-title":"Cancer immune therapy for philadelphia chromosome-negative chronic myeloproliferative neoplasms","volume":"12","author":"Holmstr\u00f6m","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.acthis.2024.152183_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108821","article-title":"Abnormal immune function of MDSC and NK cells from chronic phase CML patients restores with tyrosine kinase inhibitors","volume":"109","author":"Hong","year":"2022","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.acthis.2024.152183_bib51","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fimmu.2018.00151","article-title":"The Role of Indoleamine-2,3-dioxygenase in cancer development, diagnostics, and therapy","volume":"9","author":"Horny\u00e1k","year":"2018","journal-title":"Front Immunol."},{"issue":"16","key":"10.1016\/j.acthis.2024.152183_bib52","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1182\/blood.2022017416","article-title":"Biology and therapeutic targeting of molecular mechanisms in MPNs","volume":"141","author":"How","year":"2023","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.acthis.2024.152183_bib53","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"Huang","year":"2012","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.acthis.2024.152183_bib54","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.acthis.2024.152183_bib55","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1002\/cam4.3360","article-title":"Immunosuppressive role of CD11b+ CD33+ HLA-DR- myeloid-derived suppressor cells-like blast subpopulation in acute myeloid leukemia","volume":"9","author":"Hyun","year":"2020","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.acthis.2024.152183_bib56","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"9","key":"10.1016\/j.acthis.2024.152183_bib57","article-title":"FLT3 mutations in acute myeloid leukemia: unraveling the molecular mechanisms and implications for targeted therapies","volume":"15","author":"Jalte","year":"2023","journal-title":"Cureus"},{"issue":"37","key":"10.1016\/j.acthis.2024.152183_bib58","doi-asserted-by":"crossref","first-page":"16280","DOI":"10.1073\/pnas.1004408107","article-title":"Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein","volume":"107","author":"J\u00e4r\u00e5s","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"10","key":"10.1016\/j.acthis.2024.152183_bib59","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1002\/ijc.29297","article-title":"Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients","volume":"136","author":"Jiang","year":"2015","journal-title":"Int J. Cancer"},{"issue":"1","key":"10.1016\/j.acthis.2024.152183_bib60","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2248826","article-title":"CAR-T cells dual-target CD123 and NKG2DLs to eradicate AML cells and selectively target immunosuppressive cells","volume":"12","author":"Jin","year":"2023","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.acthis.2024.152183_bib61","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s40425-018-0432-9","article-title":"CD33\/CD3-bispecific T-cell engaging (BiTE\u00ae) antibody construct targets monocytic AML myeloid-derived suppressor cells","volume":"6","author":"Jitschin","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"17","key":"10.1016\/j.acthis.2024.152183_bib62","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.7314\/APJCP.2015.16.17.7415","article-title":"Chronic myeloid leukemia--prognostic value of mutations","volume":"16","author":"Kaleem","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.acthis.2024.152183_bib63","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40880-016-0108-0","article-title":"The Philadelphia chromosome in leukemogenesis","volume":"35","author":"Kang","year":"2016","journal-title":"Chin. J. Cancer"},{"issue":"4","key":"10.1016\/j.acthis.2024.152183_bib64","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.semcancer.2012.02.008","article-title":"New insights into chronic inflammation-induced immunosuppression","volume":"22","author":"Kanterman","year":"2012","journal-title":"Semin Cancer Biol."},{"key":"10.1016\/j.acthis.2024.152183_bib65","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/978-3-031-26163-3_15","article-title":"Increase in frequency of myeloid-derived suppressor cells in the bone marrow of myeloproliferative neoplasm: potential implications in myelofibrosis","volume":"1408","author":"Kapor","year":"2023","journal-title":"Adv. Exp. Med Biol."},{"issue":"8","key":"10.1016\/j.acthis.2024.152183_bib66","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/icb.2013.29","article-title":"Myeloid-derived suppressor cells in cancer: recent progress and prospects","volume":"91","author":"Khaled","year":"2013","journal-title":"Immunol. Cell Biol."},{"issue":"3","key":"10.1016\/j.acthis.2024.152183_bib67","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s12013-011-9319-9","article-title":"Unresolved inflammation and cancer: loss of natural immune surveillance as the correct 'target' for therapy! Seeing the 'Elephant' in the light of logic","volume":"62","author":"Khatami","year":"2012","journal-title":"Cell Biochem Biophys."},{"key":"10.1016\/j.acthis.2024.152183_bib68","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.acthis.2024.152183_bib69","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1062208","article-title":"Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome","volume":"5","author":"Kittang","year":"2015","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.acthis.2024.152183_bib70","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.acthis.2024.152183_bib71","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2141.2009.07593.x","article-title":"IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome","volume":"145","author":"Kordasti","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.acthis.2024.152183_bib72","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0301-472X(01)00789-5","article-title":"Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera","volume":"30","author":"Kralovics","year":"2002","journal-title":"Exp. Hematol."},{"issue":"11","key":"10.1016\/j.acthis.2024.152183_bib73","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/nm.3364","article-title":"Differential regulation of myeloid leukemias by the bone marrow microenvironment","volume":"19","author":"Krause","year":"2013","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.acthis.2024.152183_bib74","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/cjp2.240","article-title":"PD-L1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients","volume":"8","author":"Lee","year":"2022","journal-title":"J. Pathol. Clin. Res"},{"issue":"4","key":"10.1016\/j.acthis.2024.152183_bib75","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1158\/0008-5472.CAN-11-1792","article-title":"Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment","volume":"72","author":"Lesokhin","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.acthis.2024.152183_bib76","article-title":"Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in cancer","volume":"248","author":"Li","year":"2023","journal-title":"Pathol. Res Pr."},{"issue":"1","key":"10.1016\/j.acthis.2024.152183_bib77","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12943-022-01541-9","article-title":"A novel approach for relapsed\/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv\/NKG2D-CAR T cells and gilteritinib","volume":"21","author":"Li","year":"2022","journal-title":"Mol. Cancer"},{"issue":"10","key":"10.1016\/j.acthis.2024.152183_bib78","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.3390\/ijms21103599","article-title":"Understanding the differentiation, expansion, recruitment and suppressive activities of myeloid-derived suppressor cells in cancers","volume":"21","author":"Lim","year":"2020","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.acthis.2024.152183_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.618387","article-title":"Befriending the hostile tumor microenvironment in CAR T-cell therapy","volume":"11","author":"Lindo","year":"2021","journal-title":"Front Immunol."},{"issue":"7","key":"10.1016\/j.acthis.2024.152183_bib80","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/ijc.33865","article-title":"CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells","volume":"150","author":"Liu","year":"2022","journal-title":"Int J. Cancer"},{"issue":"15","key":"10.1016\/j.acthis.2024.152183_bib81","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1182\/bloodadvances.2018019224","article-title":"Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories","volume":"2","author":"Loghavi","year":"2018","journal-title":"Blood Adv."},{"issue":"12","key":"10.1016\/j.acthis.2024.152183_bib82","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1247135","article-title":"The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells","volume":"5","author":"Lu","year":"2016","journal-title":"Oncoimmunology"},{"issue":"16","key":"10.1016\/j.acthis.2024.152183_bib83","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1182\/blood.2022017578","article-title":"Genetic basis and molecular profiling in myeloproliferative neoplasms","volume":"141","author":"Luque Paz","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.acthis.2024.152183_bib84","article-title":"Increased levels of circulating monocytic- and early-stage myeloid-derived suppressor cells (MDSC) in acute myeloid leukemia","volume":"67","author":"Lv","year":"2021","journal-title":"Clin. Lab"},{"issue":"8","key":"10.1016\/j.acthis.2024.152183_bib85","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1002\/cncr.22570","article-title":"Myelodysplastic syndromes: incidence and survival in the United States","volume":"109","author":"Ma","year":"2007","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.acthis.2024.152183_bib86","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1182\/blood-2010-06-292433","article-title":"CBLB, TET2, ASXL1, and IDH1\/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia","volume":"117","author":"Makishima","year":"2011","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.acthis.2024.152183_bib87","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","article-title":"T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia","volume":"122","author":"Mardiros","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.acthis.2024.152183_bib88","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1172\/JCI80005","article-title":"Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected","volume":"125","author":"Marvel","year":"2015","journal-title":"J. Clin. Invest"},{"issue":"4","key":"10.1016\/j.acthis.2024.152183_bib89","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/ajh.26461","article-title":"PD-L1 overexpression correlates with JAK2-V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms","volume":"97","author":"Milosevic Feenstra","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.acthis.2024.152183_bib90","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3390\/cells10010117","article-title":"Chronic myeloid leukemia: a model disease of the past, present and future","volume":"10","author":"Minciacchi","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.acthis.2024.152183_bib91","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/dvdy.339","article-title":"Transforming growth factor-beta1 and myeloid-derived suppressor cells: a cancerous partnership","volume":"251","author":"Mojsilovic","year":"2022","journal-title":"Dev. Dyn."},{"issue":"6-7","key":"10.1016\/j.acthis.2024.152183_bib92","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3109\/08820139.2012.673191","article-title":"Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship","volume":"41","author":"Monu","year":"2012","journal-title":"Immunol. Invest"},{"key":"10.1016\/j.acthis.2024.152183_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.637725","article-title":"Immunomodulatory properties of mesenchymal stromal cells: an update","volume":"9","author":"M\u00fcller","year":"2021","journal-title":"Front Cell Dev. Biol."},{"issue":"12","key":"10.1016\/j.acthis.2024.152183_bib94","first-page":"1261","article-title":"Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies","volume":"86","author":"Mu\u00f1oz","year":"2001","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.acthis.2024.152183_bib95","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.4049\/jimmunol.0902661","article-title":"Mechanism of T cell tolerance induced by myeloid-derived suppressor cells","volume":"184","author":"Nagaraj","year":"2010","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.acthis.2024.152183_bib96","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.3390\/ijms22041906","article-title":"Inflammatory Microenvironment and Specific T cells in myeloproliferative neoplasms: immunopathogenesis and novel immunotherapies","volume":"22","author":"Nasillo","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.acthis.2024.152183_bib97","doi-asserted-by":"crossref","DOI":"10.1038\/cddiscovery.2017.2","article-title":"Haematopoietic stem cells: past, present and future","volume":"3","author":"Ng","year":"2017","journal-title":"Cell Death Discov."},{"issue":"4","key":"10.1016\/j.acthis.2024.152183_bib98","article-title":"Cytogenetics and molecular genetics of myelodysplastic neoplasms","volume":"36","author":"Ning","year":"2023","journal-title":"Best. Pr. Res Clin. Haematol."},{"issue":"5","key":"10.1016\/j.acthis.2024.152183_bib99","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J. Exp. Med."},{"issue":"8","key":"10.1016\/j.acthis.2024.152183_bib100","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.4049\/jimmunol.0802740","article-title":"Myeloid-derived suppressor cells: linking inflammation and cancer","volume":"182","author":"Ostrand-Rosenberg","year":"2009","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.acthis.2024.152183_bib101","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1073\/pnas.1222861110","article-title":"Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes","volume":"110","author":"Pang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"20","key":"10.1016\/j.acthis.2024.152183_bib102","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.1158\/0008-5472.CAN-13-2347","article-title":"HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells","volume":"74","author":"Parker","year":"2014","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.acthis.2024.152183_bib103","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/MOH.0000000000000218","article-title":"New molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms","volume":"23","author":"Passamonti","year":"2016","journal-title":"Curr. Opin. Hematol."},{"issue":"2","key":"10.1016\/j.acthis.2024.152183_bib104","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00005-018-0531-9","article-title":"Roles of myeloid-derived suppressor cells in cancer metastasis: immunosuppression and beyond","volume":"67","author":"Pastaki Khoshbin","year":"2019","journal-title":"Arch. Immunol. Ther. Exp. (Warsz. )"},{"issue":"12","key":"10.1016\/j.acthis.2024.152183_bib105","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005769","article-title":"Activated NK cells reprogram MDSCs via NKG2D-NKG2DL and IFN-\u03b3 to modulate antitumor T-cell response after cryo-thermal therapy","volume":"10","author":"Peng","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.acthis.2024.152183_bib106","article-title":"The molecular landscape of myeloproliferative neoplasms associated with splanchnic vein thrombosis: current perspective","volume":"136","author":"Pescia","year":"2023","journal-title":"Leuk. Res"},{"issue":"21","key":"10.1016\/j.acthis.2024.152183_bib107","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1111\/jcmm.17576","article-title":"Peripheral levels of monocytic myeloid-derived suppressive cells before and after first induction predict relapse and survivals in AML patients","volume":"26","author":"Peterlin","year":"2022","journal-title":"J. Cell Mol. Med"},{"issue":"8","key":"10.1016\/j.acthis.2024.152183_bib108","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/leu.2014.62","article-title":"Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo","volume":"28","author":"Pizzitola","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.acthis.2024.152183_bib109","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.ctrv.2007.07.021","article-title":"The pathogenesis of myelodysplastic syndromes (MDS)","volume":"33","author":"Platzbecker","year":"2007","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.acthis.2024.152183_bib110","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-016-0263-4","article-title":"Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications","volume":"9","author":"Pleyer","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.acthis.2024.152183_bib111","series-title":"Chronic Myeloid Neoplasias and Clonal Overlap Syndromes: Epidemiology, Pathophysiology and Treatment Options","first-page":"153","article-title":"Myelodysplastic syndromes (MDS)","author":"Pleyer","year":"2010"},{"issue":"429","key":"10.1016\/j.acthis.2024.152183_bib112","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7729","article-title":"Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms","volume":"10","author":"Prestipino","year":"2018","journal-title":"Sci. Transl. Med"},{"issue":"24","key":"10.1016\/j.acthis.2024.152183_bib113","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.3390\/cancers15245888","article-title":"Clinical, histopathological and molecular spectrum of cutaneous lesions in myelodysplastic syndrome and myeloproliferative neoplasms (MDS\/MPN): an integrative review","volume":"15","author":"Prieto-Torres","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.acthis.2024.152183_bib114","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1002\/ijc.30232","article-title":"Myeloid-derived suppressor cells as effectors of immune suppression in cancer","volume":"139","author":"Pyzer","year":"2016","journal-title":"Int J. Cancer"},{"issue":"13","key":"10.1016\/j.acthis.2024.152183_bib115","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1182\/blood-2016-07-730614","article-title":"MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia","volume":"129","author":"Pyzer","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.acthis.2024.152183_bib116","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1080\/10428194.2020.1817431","article-title":"Increased myeloid-derived suppressor cells in patients with myelodysplastic syndromes suppress CD8+ T lymphocyte function through the STAT3-ARG1 pathway","volume":"62","author":"Qi","year":"2021","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.acthis.2024.152183_bib117","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48635-x","article-title":"Exhaustion of CD4+ T-cells mediated by the Kynurenine Pathway in Melanoma","volume":"9","author":"Rad Pour","year":"2019","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.acthis.2024.152183_bib118","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nrrheum.2015.160","article-title":"Navigating the bone marrow niche: translational insights and cancer-driven dysfunction","volume":"12","author":"Reagan","year":"2016","journal-title":"Nat. Rev. Rheuma"},{"issue":"Suppl 1","key":"10.1016\/j.acthis.2024.152183_bib119","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/annonc\/mdl443","article-title":"Epidemiology of hematological malignancies","volume":"18","author":"Rodriguez-Abreu","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.acthis.2024.152183_bib120","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.coi.2016.06.004","article-title":"Chimeric antigen receptors: driving immunology towards synthetic biology","volume":"41","author":"Sadelain","year":"2016","journal-title":"Curr. Opin. Immunol."},{"issue":"10","key":"10.1016\/j.acthis.2024.152183_bib121","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1007\/s00018-019-03048-x","article-title":"Immunosenescence: the potential role of myeloid-derived suppressor cells (MDSC) in age-related immune deficiency","volume":"76","author":"Salminen","year":"2019","journal-title":"Cell Mol. Life Sci."},{"issue":"2","key":"10.1016\/j.acthis.2024.152183_bib122","doi-asserted-by":"crossref","DOI":"10.1002\/acg2.78","article-title":"Update on the classification of myeloid neoplasms: The 2016 revised World Health Organization classification of hematopoietic and lymphoid neoplasms","volume":"3","author":"Sangiorgio","year":"2020","journal-title":"Adv. Cell Gene Ther."},{"key":"10.1016\/j.acthis.2024.152183_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100706","article-title":"Epidemiology of the classical myeloproliferative neoplasms: the four corners of an expansive and complex map","volume":"42","author":"Shallis","year":"2020","journal-title":"Blood Rev."},{"issue":"7","key":"10.1016\/j.acthis.2024.152183_bib124","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/mc.23206","article-title":"Myeloid derived suppressor cells in cancer, premalignancy and inflammation: a roadmap to cancer immunoprevention","volume":"59","author":"Sivagnanalingam","year":"2020","journal-title":"Mol. Carcinog."},{"issue":"22","key":"10.1016\/j.acthis.2024.152183_bib125","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1056\/NEJMra1406186","article-title":"Myeloproliferative neoplasms","volume":"376","author":"Spivak","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.acthis.2024.152183_bib126","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/0008-5472.CAN-09-2587","article-title":"Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine","volume":"70","author":"Srivastava","year":"2010","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.acthis.2024.152183_bib127","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.critrevonc.2004.10.012","article-title":"The molecular pathogenesis of acute myeloid leukemia","volume":"56","author":"Steffen","year":"2005","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.acthis.2024.152183_bib128","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.exphem.2019.05.002","article-title":"CD123 CAR T cells for the treatment of myelodysplastic syndrome","volume":"74","author":"Stevens","year":"2019","journal-title":"Exp. Hematol."},{"issue":"16","key":"10.1016\/j.acthis.2024.152183_bib129","doi-asserted-by":"crossref","first-page":"12700","DOI":"10.3390\/ijms241612700","article-title":"Molecular studies for the early detection of philadelphia-negative myeloproliferative neoplasms","volume":"24","author":"Stuckey","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.acthis.2024.152183_bib130","doi-asserted-by":"crossref","first-page":"175","DOI":"10.7150\/ijbs.86305","article-title":"Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"20","author":"Sun","year":"2024","journal-title":"Int J. Biol. Sci."},{"issue":"5","key":"10.1016\/j.acthis.2024.152183_bib131","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s12185-015-1865-2","article-title":"Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia","volume":"102","author":"Sun","year":"2015","journal-title":"Int J. Hematol."},{"key":"10.1016\/j.acthis.2024.152183_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103164","article-title":"Immune evasion mechanisms in acute myeloid leukemia: a focus on immune checkpoint pathways","volume":"157","author":"Taghiloo","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"10","key":"10.1016\/j.acthis.2024.152183_bib133","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nrc3581","article-title":"History of myeloid-derived suppressor cells","volume":"13","author":"Talmadge","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.acthis.2024.152183_bib134","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6616391","article-title":"T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies","volume":"2021","author":"Tang","year":"2021","journal-title":"Biomed. Res Int"},{"issue":"16","key":"10.1016\/j.acthis.2024.152183_bib135","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.acthis.2024.152183_bib136","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/10428194.2023.2277674","article-title":"Understanding triple negative myeloproliferative neoplasms: pathogenesis, clinical features, and management","volume":"65","author":"Tharakan","year":"2024","journal-title":"Leuk. Lymphoma"},{"issue":"7","key":"10.1016\/j.acthis.2024.152183_bib137","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131761","article-title":"The profile of t helper subsets in bone marrow microenvironment is distinct for different stages of acute myeloid leukemia patients and chemotherapy partly ameliorates these variations","volume":"10","author":"Tian","year":"2015","journal-title":"PLoS One"},{"issue":"17","key":"10.1016\/j.acthis.2024.152183_bib138","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1158\/0008-5472.CAN-20-0024","article-title":"Palmitoylated proteins on AML-derived extracellular vesicles promote myeloid-derived suppressor cell differentiation via TLR2\/Akt\/mTOR signaling","volume":"80","author":"Tohumeken","year":"2020","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.acthis.2024.152183_bib139","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood-2006-11-060087","article-title":"Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy","volume":"110","author":"Tsushima","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.acthis.2024.152183_bib140","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.638841","article-title":"Interaction Between MDSC and NK cells in solid and hematological malignancies: impact on HSCT","volume":"12","author":"Tumino","year":"2021","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.acthis.2024.152183_bib141","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13045-021-01193-0","article-title":"Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma","volume":"14","author":"Tumino","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.acthis.2024.152183_bib142","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.3390\/biomedicines11102613","article-title":"Emerging insights into molecular mechanisms of inflammation in myelodysplastic syndromes","volume":"11","author":"Vallelonga","year":"2023","journal-title":"Biomedicines"},{"issue":"8","key":"10.1016\/j.acthis.2024.152183_bib143","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.exphem.2015.05.016","article-title":"Deconstructing innate immune signaling in myelodysplastic syndromes","volume":"43","author":"Varney","year":"2015","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.acthis.2024.152183_bib144","doi-asserted-by":"crossref","unstructured":"Vgenopoulou, P., Kousteni, S., 2020. The Bone Marrow Stromal Niche: A New Master Regulator of Hematological Myeloid Malignancies. (225-235). doi:10.1016\/b978-0-12-801238-3.11257-7.","DOI":"10.1016\/B978-0-12-801238-3.11257-7"},{"issue":"4","key":"10.1016\/j.acthis.2024.152183_bib145","doi-asserted-by":"crossref","first-page":"216","DOI":"10.5045\/br.2014.49.4.216","article-title":"Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease","volume":"49","author":"Visconte","year":"2014","journal-title":"Blood Res."},{"key":"10.1016\/j.acthis.2024.152183_bib146","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3389\/fimmu.2019.00172","article-title":"MDSCs: key criminals of tumor pre-metastatic niche formation","volume":"10","author":"Wang","year":"2019","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.acthis.2024.152183_bib147","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13045-019-0746-1","article-title":"Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies","volume":"12","author":"Wang","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.acthis.2024.152183_bib148","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.leukres.2016.02.004","article-title":"Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm","volume":"43","author":"Wang","year":"2016","journal-title":"Leuk. Res"},{"key":"10.1016\/j.acthis.2024.152183_bib149","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/7363084","article-title":"Circulating monocytic myeloid-derived suppressor cells are elevated and associated with poor prognosis in acute myeloid leukemia","volume":"2020","author":"Wang","year":"2020","journal-title":"J. Immunol. Res"},{"issue":"1","key":"10.1016\/j.acthis.2024.152183_bib150","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.acthis.2024.152183_bib151","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13045-020-00939-6","article-title":"Dendritic cell biology and its role in tumor immunotherapy","volume":"13","author":"Wang","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.acthis.2024.152183_bib152","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1158\/0008-5472.CAN-18-1078","article-title":"CML hematopoietic stem cells expressing IL1RAP can be targeted by chimeric antigen receptor-engineered T cells","volume":"79","author":"Warda","year":"2019","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.acthis.2024.152183_bib153","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006857","article-title":"Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia","volume":"11","author":"Wen","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.acthis.2024.152183_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116132","article-title":"Immunotherapies of acute myeloid leukemia: rationale, clinical evidence and perspective","volume":"171","author":"Wu","year":"2024","journal-title":"Biomed. Pharm."},{"issue":"1","key":"10.1016\/j.acthis.2024.152183_bib155","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/10428194.2019.1658098","article-title":"The interaction of tumor cells and myeloid-derived suppressor cells in chronic myelogenous leukemia","volume":"61","author":"Xu","year":"2020","journal-title":"Leuk. Lymphoma"},{"issue":"15","key":"10.1016\/j.acthis.2024.152183_bib156","doi-asserted-by":"crossref","first-page":"12502","DOI":"10.3390\/ijms241512502","article-title":"Role of next generation immune checkpoint inhibitor (ICI) therapy in philadelphia negative classic myeloproliferative neoplasm (MPN): review of the literature","volume":"24","author":"Yadav","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.acthis.2024.152183_bib157","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-020-0843-1","article-title":"Myeloid-derived suppressor cells-new and exciting players in lung cancer","volume":"13","author":"Yang","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.acthis.2024.152183_bib158","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40164-022-00263-4","article-title":"Targeting PD-1\/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia","volume":"11","author":"Yang","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.acthis.2024.152183_bib159","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.3109\/10428194.2014.987141","article-title":"Myeloid-derived suppressor cells: their role in the pathophysiology of hematologic malignancies and potential as therapeutic targets","volume":"56","author":"Younos","year":"2015","journal-title":"Leuk. Lymphoma"},{"issue":"2","key":"10.1016\/j.acthis.2024.152183_bib160","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/imm.13488","article-title":"TIM3\/CEACAM1 pathway involves in myeloid-derived suppressor cells induced CD8+ T cells exhaustion and bone marrow inflammatory microenvironment in myelodysplastic syndrome","volume":"168","author":"Yu","year":"2023","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.acthis.2024.152183_bib161","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2166333","article-title":"Myeloid-derived suppressor cells inhibit natural killer cells in myelodysplastic syndromes through the TIGIT\/CD155 pathway","volume":"28","author":"Yue","year":"2023","journal-title":"Hematology"},{"issue":"2","key":"10.1016\/j.acthis.2024.152183_bib162","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2567.2012.03566.x","article-title":"S100A9 a new marker for monocytic human myeloid-derived suppressor cells","volume":"136","author":"Zhao","year":"2012","journal-title":"Immunology"},{"issue":"2","key":"10.1016\/j.acthis.2024.152183_bib163","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1004983","article-title":"Phenotype, development, and biological function of myeloid-derived suppressor cells","volume":"5","author":"Zhao","year":"2015","journal-title":"Oncoimmunology"},{"issue":"6","key":"10.1016\/j.acthis.2024.152183_bib164","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11899-018-0474-6","article-title":"Chronic myeloid leukemia: beyond BCR-ABL1","volume":"13","author":"Zhou","year":"2018","journal-title":"Curr. Hematol. Malig. Rep."}],"container-title":["Acta Histochemica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065128124000515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065128124000515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:27:44Z","timestamp":1777472864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065128124000515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":164,"journal-issue":{"issue":"5-7","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0065128124000515"],"URL":"https:\/\/doi.org\/10.1016\/j.acthis.2024.152183","relation":{},"ISSN":["0065-1281"],"issn-type":[{"value":"0065-1281","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myeloid-derived suppressor cells: Implication in myeloid malignancies and immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Acta Histochemica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acthis.2024.152183","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152183"}}